The Rise Of Impact Of Personalized Medicine On The Growth Of The Carticel Service Is Influencing The Antivirals Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Antivirals Market Projected To Reach By 2030?

The antivirals market has experienced significant growth in recent years. This market is anticipated to expand from $114.4 billion in 2025 to $122.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. Several factors have contributed to its historical growth, including widespread global viral outbreaks, the persistent burden of HIV and hepatitis, government initiatives for antiviral stockpiling, the increasing availability of generic medications, and the expansion of infectious disease programs.

The antivirals market is anticipated to show substantial growth in the upcoming years. It is projected to expand to $163.33 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is attributed to factors such as emerging viral threats, increased investment in antiviral research and development, enhanced vaccination and treatment integration, global health initiatives, and a demand for rapid-response therapeutics. Significant trends in the forecast period include a rising demand for broad-spectrum antivirals, a growing emphasis on pandemic preparedness, the expansion of generic antiviral drugs, increased usage in chronic viral infections, and the development of novel mechanism antivirals.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp

What Factors Are Contributing To The Growth Of The Antivirals Market?

A growing occurrence of influenza is expected to stimulate the expansion of the antiviral market moving ahead. Influenza, commonly known as the flu, is a highly transmissible viral respiratory infection caused by influenza viruses, impacting the nose, throat, and lungs. The increasing spread of influenza is largely attributable to colder conditions and indoor congregations, factors that extend the virus’s survival and promote close-contact transmission between individuals. Antivirals serve in treating influenza, functioning to hinder the reproduction and dissemination of influenza viruses inside the body. As an illustration, in November 2024, the Centers for Disease Control and Prevention, a national public health agency based in the US, reported that the 2023 to 2024 influenza season was estimated to have resulted in 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the heightened frequency of influenza cases is boosting the expansion of the antiviral market.

How Is Segmentation Applied In The Antivirals Market Segment Analysis?

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

What Market Trends Are Affecting The Antivirals Market?

Leading companies in the antiviral market are concentrating on developing groundbreaking treatments, like oral antiviral options, to enhance patient adherence, increase availability, lower healthcare expenditures, and provide more convenient and effective methods for managing viral illnesses. Oral antiviral treatments are medicines taken orally to combat viral infections. These therapies function by hindering viruses from replicating or spreading within the body, which helps to diminish the infection’s severity and duration. For instance, in May 2023, US-based pharmaceutical company Pfizer announced that Paxlovid received approval from the US government agency, the Food and Drug Administration, as the first oral antiviral treatment for COVID-19 in adults. This approval holds particular importance as it introduces a new therapeutic avenue for managing COVID-19, especially as the pandemic moves towards an endemic phase. Paxlovid is specifically prescribed for adults with mild-to-moderate COVID-19 who are at elevated risk for advancing to severe disease, including needing hospitalization or facing death.

Prominent companies within the antiviral market are dedicated to developing advanced therapeutic solutions, such as new antiviral treatments, to improve patient results and lessen viral transmission. Antiviral treatments are crucial for managing viral infections and preventing severe complications in patients. For example, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, introduced versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm specializing in developing broad-spectrum antiviral treatments. The company focuses on infectious pathogens such as COVID-19 and influenza, having successfully moved a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen uses stapled lipopeptides to inhibit viral fusion and block the entry of viruses into cells.

Who Are The Companies Participating In The Antivirals Market Environment?

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Get The Full Antivirals Market Report:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Which Region Leads The Antivirals Market In Terms Of Market Share?

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antivirals Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Browse Through More Reports Similar to the Global Antivirals Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795